209 related articles for article (PubMed ID: 34347188)
1. Evaluation of care delivery by a novel multidisciplinary bone health clinic for patients at risk of glucocorticoid-induced osteoporosis.
Abdullah H; Koller G; Zuna I; Yuksel N; Charrois T; Mandhane R; Cotton K; Danilak M; Bell H; Ye C
Arch Osteoporos; 2021 Jul; 16(1):108. PubMed ID: 34347188
[TBL] [Abstract][Full Text] [Related]
2. Glucocorticoid-induced osteoporosis preventive care in rheumatology patients.
Koller G; Katz S; Charrois TL; Ye C
Arch Osteoporos; 2019 Feb; 14(1):16. PubMed ID: 30723883
[TBL] [Abstract][Full Text] [Related]
3. Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club.
Laurent MR; Goemaere S; Verroken C; Bergmann P; Body JJ; Bruyère O; Cavalier E; Rozenberg S; Lapauw B; Gielen E
Front Endocrinol (Lausanne); 2022; 13():908727. PubMed ID: 35757436
[TBL] [Abstract][Full Text] [Related]
4. Status of Glucocorticoid-Induced Osteoporosis Preventive Care in Korea: A Retrospective Cohort Study on the Korean National Health Insurance Service Database.
Song BW; Kim AR; Kim MA; Kim HS; Lee SG
Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208647
[No Abstract] [Full Text] [Related]
5. Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures.
Gourlay M; Franceschini N; Sheyn Y
Clin Rheumatol; 2007 Feb; 26(2):144-53. PubMed ID: 16670825
[TBL] [Abstract][Full Text] [Related]
6. The disconnect between better quality of glucocorticoid-induced osteoporosis preventive care and better outcomes: a population-based cohort study.
Majumdar SR; Lix LM; Morin SN; Yogendran M; Metge CJ; Leslie WD
J Rheumatol; 2013 Oct; 40(10):1736-41. PubMed ID: 23818715
[TBL] [Abstract][Full Text] [Related]
7. Glucocorticoid-induced Osteoporosis.
Whittier X; Saag KG
Rheum Dis Clin North Am; 2016 Feb; 42(1):177-89, x. PubMed ID: 26611558
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of bisphosphonates for prevention of fracture related to glucocorticoid-induced osteoporosis in Malaysia.
Mohd-Tahir NA; Thomas P; Mohamed-Said MS; Makmor-Bakry M; Li SC
Int J Rheum Dis; 2018 Mar; 21(3):647-655. PubMed ID: 29105349
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study.
Rossini M; Viapiana O; Vitiello M; Malavolta N; La Montagna G; Maddali Bongi S; Di Munno O; Nuti R; Manzini CU; Ferri C; Bogliolo L; Mathieu A; Cantatore F; Del Puente A; Muratore M; Grassi W; Frediani B; Saviola G; Delvino P; Mirone L; Ferraccioli G; Tripi G; Piazza I; Gatti D
Reumatismo; 2017 May; 69(1):30-39. PubMed ID: 28535619
[TBL] [Abstract][Full Text] [Related]
10. Glucocorticoid-induced osteoporosis: 2019 concise clinical review.
Adami G; Saag KG
Osteoporos Int; 2019 Jun; 30(6):1145-1156. PubMed ID: 30805679
[TBL] [Abstract][Full Text] [Related]
11. Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions.
Bultink IE; Baden M; Lems WF
Expert Opin Pharmacother; 2013 Feb; 14(2):185-97. PubMed ID: 23317448
[TBL] [Abstract][Full Text] [Related]
12. [Assessment of the treatment of glucocorticoid-induced osteoporosis].
Asano S; Suzuki A
Clin Calcium; 2013 Mar; 23(3):401-8. PubMed ID: 23445894
[TBL] [Abstract][Full Text] [Related]
13. Population-based trends in osteoporosis management after new initiations of long-term systemic glucocorticoids (1998-2008).
Majumdar SR; Lix LM; Yogendran M; Morin SN; Metge CJ; Leslie WD
J Clin Endocrinol Metab; 2012 Apr; 97(4):1236-42. PubMed ID: 22298803
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and risk factors associated with glucocorticoid-induced osteoporosis in Chinese patients with rheumatoid arthritis.
Ma CC; Xu SQ; Gong X; Wu Y; Qi S; Liu W; Xu JH
Arch Osteoporos; 2017 Dec; 12(1):33. PubMed ID: 28374332
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D and bisphosphonate therapy in systemic lupus erythematosus patients who receive glucocorticoids: are we offering the best care?
Sapkota S; Baig S; Hess T; O'Connell AM; Menk J; Shyne M; Fazeli P; Ensrud K; Shmagel A
Lupus; 2020 Mar; 29(3):263-272. PubMed ID: 31996109
[TBL] [Abstract][Full Text] [Related]
16. Fracture risk associated with glucocorticoid-induced osteoporosis in Japan.
Soen S; Kaku M; Okubo N; Onishi Y; Saito K; Kobayashi M
J Bone Miner Metab; 2022 Jul; 40(4):636-647. PubMed ID: 35546370
[TBL] [Abstract][Full Text] [Related]
17. [Secondary osteoporosis or secondary contributors to bone loss in fracture. Therapeutic strategy for glucocorticoid-induced osteoporosis].
Hayakawa N; Suzuki A
Clin Calcium; 2013 Sep; 23(9):1337-44. PubMed ID: 23999371
[TBL] [Abstract][Full Text] [Related]
18. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis.
Feldstein AC; Elmer PJ; Nichols GA; Herson M
Osteoporos Int; 2005 Dec; 16(12):2168-74. PubMed ID: 16142501
[TBL] [Abstract][Full Text] [Related]
19. Management of glucocorticoid-induced osteoporosis.
Rizzoli R; Adachi JD; Cooper C; Dere W; Devogelaer JP; Diez-Perez A; Kanis JA; Laslop A; Mitlak B; Papapoulos S; Ralston S; Reiter S; Werhya G; Reginster JY
Calcif Tissue Int; 2012 Oct; 91(4):225-43. PubMed ID: 22878667
[TBL] [Abstract][Full Text] [Related]
20. Glucocorticoid-induced osteoporosis: who to treat with what agent?
Rizzoli R; Biver E
Nat Rev Rheumatol; 2015 Feb; 11(2):98-109. PubMed ID: 25385412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
